Ogieuhi Ikponmwosa Jude, Ajekiigbe Victor Oluwatomiwa, Oladipo Tolu Comfort, Oyenuga Adedamola Solomon, Olaiya Victor Olamiposi, Anthony Chidera Stanley, Agbo Chinonyelum Emmanuel, Abdallah Weam Salih, Akingbola Adewunmi, Ntukidem Olanipekun Lanny
Siberian State Medical University, Tomsk, Russia.
Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
Clin Transl Oncol. 2025 Jul 5. doi: 10.1007/s12094-025-03980-4.
Small-cell lung cancer remains one of the most aggressive lung malignancies, a neuroendocrine tumor with paraneoplastic features; it often grows centrally in the lung as opposed to peripheral cancers. Small-cell lung cancer (SCLC) is managed by chemotherapy and/or radiation. Due to its aggressive nature and poor prognosis, there is a need for more targeted and effective therapies; hence, the emergence of tarlatamab, a bispecific T-cell engager (BiTE), shows promise in current clinical trials. This review critically assesses the efficacy of tarlatamab in demonstrating antineoplastic activity. We also assess the safety profile, overall survival rate, progression-free survival, duration of response, and immunogenicity.
To conduct this review, a thorough preliminary search was conducted to identify key studies that evaluated the medication at specific doses among patients with small-cell lung cancer.
The positive and negative outcomes are discussed in this review, along with safety, tolerability, and performance in relapsed and refractory SLCL and biomarker insights. The adverse effects were generally manageable, most occurring during the first treatment cycle. The unique mechanism of action of tarlatamab was described with a comparative analysis with other novel monoclonal antibodies and chemotherapies for managing small-cell lung cancer (SCLC). The studies evaluated in this review are not without limitations.
Tarlatamab's use must be evaluated in a more heterogeneous population with different demographics, comorbidities, and a larger patient population. The possibility of combination therapy studies should also be evaluated in future studies to increase the efficacy of tarlatamab.
小细胞肺癌仍然是最具侵袭性的肺部恶性肿瘤之一，是一种具有副肿瘤特征的神经内分泌肿瘤；与周围型癌症不同，它通常在肺中央生长。小细胞肺癌（SCLC）通过化疗和/或放疗进行治疗。由于其侵袭性本质和预后不良，需要更具针对性和有效的治疗方法；因此，双特异性T细胞衔接器（BiTE）药物tarlatamab在当前临床试验中显示出前景。本综述批判性地评估了tarlatamab在显示抗肿瘤活性方面的疗效。我们还评估了其安全性、总生存率、无进展生存期、缓解持续时间和免疫原性。
为进行本综述，进行了全面的初步检索，以确定在小细胞肺癌患者中评估特定剂量该药物的关键研究。
本综述讨论了阳性和阴性结果，以及复发和难治性小细胞肺癌中的安全性、耐受性和表现，以及生物标志物见解。不良反应通常可控，大多数发生在第一个治疗周期。通过与其他用于治疗小细胞肺癌（SCLC）的新型单克隆抗体和化疗药物进行比较分析，描述了tarlatamab独特的作用机制。本综述中评估的研究并非没有局限性。
必须在更具异质性的人群中评估tarlatamab的使用，这些人群具有不同的人口统计学特征、合并症，且患者数量更多。未来的研究还应评估联合治疗研究的可能性，以提高tarlatamab的疗效。
